Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab Diabetes Intervention Trial (I-DIT)
2023-508588-58-00Phase 2Authorised
- Sponsor
- University of Gothenburg
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in diabetes mellitus type 1 (T1D) comparing Ixekizumab arm with Placebo arm (2 arms). Primary endpoint: Change in residual insulin secretion (stimulated C-peptide AUC 0–2h during MMTT). Planned start Oct 2024; status: authorised.
02
Drugs
ixekizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2023-508588-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508588-58-00.